An Evolving Standard for Success: Proving Product Value Through Comparative Effectiveness Data
Nayan Nanavati - Vice President and General Manager, Peri-Approval Services Americas
Chuck Stevens - Vice President and General Manager, Reimbursement and Market Access
Inclusion of $1.1B in the Obama Stimulus Plan to support comparative effectiveness research of drugs, medical devices, surgical procedures and other treatments, is a clear indication of the US Government’s priority to obtain value in healthcare dollar spending. As it gains traction among policymakers, and as the Federal Government continues to increase its role as the largest direct payer for drugs, biologics, devices and diagnostics, we expect regulators to demand such data for new products demonstrating greater benefits over existing products.
Our expert panel will review case studies and provide key insights as to the potential future requirements for comparative effectiveness, the opportunities and challenges they pose, and strategies to address.
Webcast length: 60 minutes
To view the webcast
Click here
